Viviane Monges Sells 9,667 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Viviane Monges sold 9,667 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.29, for a total transaction of $292,813.43. Following the completion of the transaction, the director directly owned 5,500 shares of the company’s stock, valued at approximately $166,595. The trade was a 63.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Pharvaris Stock Performance

Pharvaris stock opened at $29.47 on Thursday. The firm’s fifty day moving average price is $28.66 and its 200-day moving average price is $27.01. The stock has a market cap of $1.93 billion, a P/E ratio of -9.27 and a beta of -2.34. Pharvaris N.V. has a fifty-two week low of $15.46 and a fifty-two week high of $33.33.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, analysts predict that Pharvaris N.V. will post -3.25 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on PHVS shares. Wedbush raised their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wolfe Research started coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.18.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently added to or reduced their stakes in PHVS. Wellington Management Group LLP purchased a new position in Pharvaris in the 3rd quarter worth $43,282,000. Paradigm Biocapital Advisors LP raised its position in Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after purchasing an additional 772,583 shares during the period. Balyasny Asset Management L.P. purchased a new position in Pharvaris in the 3rd quarter worth $15,613,000. Commodore Capital LP raised its position in Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares during the period. Finally, General Atlantic L.P. raised its position in Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after purchasing an additional 500,000 shares during the period.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Short interest in Pharvaris fell sharply in mid-May, dropping 42.9% to 600,645 shares. That lower bearish positioning can be viewed as a constructive signal for the stock.
• Positive Sentiment: Brokerage coverage remains supportive, with Pharvaris receiving a consensus rating of “Moderate Buy,” which suggests analysts still see meaningful upside potential. Article link
• Neutral Sentiment: The company also continues to trade near the upper end of its 52-week range after beating first-quarter EPS estimates, which helps reinforce investor confidence in the name. Article link
• Negative Sentiment: Recent insider selling by CFO David Nassif, Director Viviane Monges, and insider Anna Nijdam may be pressuring sentiment, even though some of the sales were tied to tax withholding or equity vesting. Article link

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.